Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
1(17%)
Results Posted
133%(4 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_1
2
33%
Ph phase_3
1
17%
Ph phase_2
2
33%

Phase Distribution

2

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)

Trials by Status

terminated233%
active_not_recruiting117%
completed350%

Recent Activity

1 active trials
Showing 5 of 6
active_not_recruitingphase_2

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

NCT04245839
completedphase_3

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

NCT03575351
completedphase_2

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

NCT03484702
terminatedphase_1

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

NCT03743246
completedphase_1

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

NCT03310619
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04245839Phase 2

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Active Not Recruiting
NCT03575351Phase 3

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

Completed
NCT03484702Phase 2

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

Completed
NCT03743246Phase 1

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Terminated
NCT03310619Phase 1

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Completed
NCT03436771

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6